Introduction - 27/09/17
Doi : 10.1016/j.amjmed.2017.04.003
Keywords : Cardiovascular, Empagliflozin, EMPA-REG OUTCOME, Sodium glucose cotransporter 2 inhibitors, Type 2 diabetes mellitus
El texto completo de este artículo está disponible en PDF.
| Funding: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. Writing support was provided by Geraldine Thompson of Envision Scientific Solutions, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. The author received no direct compensation related to the development of the manuscript. |
|
| Conflict of Interest: RC has received consulting fees from Boehringer Ingelheim and Eli Lilly and Company. |
|
| Authorship: The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The author was fully responsible for all content and editorial decisions, was involved at all stages of manuscript development, and approved the final version that reflects the author's interpretation and conclusions. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. |
|
| This article is co-published in The American Journal of Medicine (Vol. 130, Issue 6S, June 2017) and The American Journal of Cardiology (Vol. 120, Issue 1S, July 1, 2017). |
© 2017
Publicado por Elsevier Masson SAS.
Vol 130 - N° 6S
P. S1-S3 - juin 2017 Regresar al número
Artículo precedente
- Table of Contents
- Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
- James Thrasher
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?